OncoHost announced it has received “Proteomics Innovation of the Year” in the fifth annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough.
OncoHost’s PROphet platform is a plasma-based tool that leverages proteomic pattern recognition, bioinformatics, and AI to support and enhance clinical decision-making for oncologists. The platform’s initial offering - PROphetNSCLC, is the first liquid biopsy proteomics test designed to guide immunotherapy treatment choices in late-stage non-small cell lung cancer (NSCLC). Available throughout the U.S., PROphetNSCLC provides clinicians with actionable insights based on a single pre-treatment blood sample that captures dynamic biological processes in real time, enabling more personalized and effective therapeutic strategies.
OncoHost’s proteomics-based platform identifies circulating protein patterns that correlate with therapy resistance, sensitivity, and toxicity. Using high-throughput assays, thousands of proteins are profiled and analyzed with proprietary AI models, generating patient-specific predictive scores for both progression-free survival (PFS) and overall survival (OS). The PROphet proteomic signature has also demonstrated predictive value across melanoma, renal cell carcinoma (RCC), HPV-associated malignancies, triple-negative breast cancer (TNBC), small cell lung cancer (SCLC), and colorectal cancer.
In addition, PROphetirAE is a proteomics-based model designed to predict immune-related adverse events before treatment begins. By identifying patients at risk for substantial toxicities, oncologists can make safer, more effective therapeutic choices.
Visit OncoHost for more information
